Cikkek nyilvánosan hozzáférhető megbízással - Daniel RenoufTovábbi információ
Sehol sem hozzáférhető: 14
Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer
EY Zhao, Y Shen, E Pleasance, K Kasaian, S Leelakumari, M Jones, ...
Clinical Cancer Research 23 (24), 7521-7530, 2017
Megbízások: Canadian Institutes of Health Research
Altered gene expression along the glycolysis–cholesterol synthesis axis is associated with outcome in pancreatic cancer
JM Karasinska, JT Topham, SE Kalloger, GH Jang, RE Denroche, ...
Clinical Cancer Research 26 (1), 135-146, 2020
Megbízások: Genome Canada, Natural Sciences and Engineering Research Council of Canada …
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma
MR Jones, LM Williamson, JT Topham, MKC Lee, A Goytain, J Ho, ...
Clinical Cancer Research 25 (15), 4674-4681, 2019
Megbízások: Canadian Institutes of Health Research, Genome Canada, Natural Sciences and …
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes
E Pleasance, E Titmuss, L Williamson, H Kwan, L Culibrk, EY Zhao, ...
Nature Cancer 1 (4), 452-468, 2020
Megbízások: US National Institutes of Health, Canadian Institutes of Health Research …
Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX
RD Peixoto, M Ho, DJ Renouf, HJ Lim, S Gill, JY Ruan, WY Cheung
American journal of clinical oncology 40 (5), 507-511, 2017
Megbízások: Canadian Cancer Society
Reasons for underuse of adjuvant chemotherapy in elderly patients with stage III colon cancer
JJ Ko, HF Kennecke, HJ Lim, DJ Renouf, S Gill, R Woods, C Speers, ...
Clinical colorectal cancer 15 (2), 179-185, 2016
Megbízások: Canadian Cancer Society
Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics
JT Topham, JM Karasinska, MKC Lee, V Csizmok, LM Williamson, ...
Clinical Cancer Research 27 (1), 150-157, 2021
Megbízások: Genome Canada, Ontario Institute for Cancer Research
Impact of weight changes after the diagnosis of stage III colon cancer on survival outcomes
J Vergidis, G Gresham, HJ Lim, DJ Renouf, HF Kennecke, JY Ruan, ...
Clinical colorectal cancer 15 (1), 16-23, 2016
Megbízások: Canadian Cancer Society
Delving into early-onset pancreatic ductal adenocarcinoma: how does age fit in?
ES Tsang, JT Topham, JM Karasinska, MKC Lee, LM Williamson, ...
Clinical Cancer Research 27 (1), 246-254, 2021
Megbízások: Canadian Institutes of Health Research, Genome Canada, Natural Sciences and …
Uncovering clinically relevant gene fusions with integrated genomic and transcriptomic profiling of metastatic cancers
ES Tsang, CJ Grisdale, E Pleasance, JT Topham, K Mungall, C Reisle, ...
Clinical Cancer Research 27 (2), 522-531, 2021
Megbízások: Canadian Institutes of Health Research, Natural Sciences and Engineering …
Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer
B Dascalu, HF Kennecke, HJ Lim, DJ Renouf, JY Ruan, JT Chang, ...
Supportive Care in Cancer 24, 799-805, 2016
Megbízások: Canadian Cancer Society
Endogenous retrovirus transcript levels are associated with immunogenic signatures in multiple metastatic cancer types
JT Topham, E Titmuss, ED Pleasance, LM Williamson, JM Karasinska, ...
Molecular cancer therapeutics 19 (9), 1889-1897, 2020
Megbízások: Canadian Institutes of Health Research, Genome Canada, Natural Sciences and …
Impact of tumor location on patient outcomes in small bowel cancers
SY Irene, Z Al-Hashami, P Chapani, C Speers, JM Davies, HJ Lim, ...
Clinical colorectal cancer 21 (2), 107-113, 2022
Megbízások: US National Institutes of Health
Integration of whole-genome sequencing with circulating tumor DNA analysis captures clonal evolution and tumor heterogeneity in non-V600 BRAF mutant colorectal cancer
S Mendis, M Alcaide, JT Topham, B Johnson, RD Morin, J Chu, I Bosdet, ...
Clinical colorectal cancer 19 (2), 132-136. e3, 2020
Megbízások: US National Institutes of Health, Genome Canada
Valahol hozzáférhető: 70
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell–and patient-derived tumor organoids
L Huang, A Holtzinger, I Jagan, M BeGora, I Lohse, N Ngai, C Nostro, ...
Nature medicine 21 (11), 1364-1371, 2015
Megbízások: US National Institutes of Health, Canadian Cancer Society, Genome Canada …
Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial
EM O’Reilly, DY Oh, N Dhani, DJ Renouf, MA Lee, W Sun, G Fisher, ...
JAMA oncology 5 (10), 1431-1438, 2019
Megbízások: US National Institutes of Health
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
M Chan-Seng-Yue, JC Kim, GW Wilson, K Ng, EF Figueroa, GM O’Kane, ...
Nature genetics 52 (2), 231-240, 2020
Megbízások: Canadian Cancer Society, Canadian Institutes of Health Research, Fonds de …
Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer
L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, ...
Cancer discovery 10 (1), 40-53, 2020
Megbízások: US National Institutes of Health
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial
T Conroy, F Castan, A Lopez, A Turpin, MB Abdelghani, AC Wei, E Mitry, ...
JAMA oncology 8 (11), 1571-1578, 2022
Megbízások: Canadian Cancer Society
A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors
PC McDonald, S Chia, PL Bedard, Q Chu, M Lyle, L Tang, M Singh, ...
American journal of clinical oncology 43 (7), 484-490, 2020
Megbízások: Canadian Cancer Society, Canadian Institutes of Health Research
A publikációs és a finanszírozási adatokat számítógépes program határozza meg, automatikusan.